Veracyte Inc $ 26.5 0.45 (1.73%)
| Volume: | 1,140,434 | Avg Vol (1m): | 604,501 |
| Market Cap $: | 1.28 Bil | Enterprise Value $: | 1.11 Bil |
| P/E (TTM): | 0.00 | P/B: | 4.83 |
Manual of Stocks™ Web
Financial Strength | 7.4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 13.51 | ||
| Equity-to-Asset | 0.89 | ||
| Debt-to-Equity | 0.06 | ||
| Debt-to-EBITDA | -2.16 | ||
| Piotroski F-Score | 6 | ||
| Altman Z-Score | 27.32 | ||
| Beneish M-Score | -2.19 | ||
| WACC vs ROIC | |||
Profitability | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -11.51 | ||
| Net Margin % | -11.01 | ||
| ROE % | -12.16 | ||
| ROA % | -8.8 | ||
| ROC (Joel Greenblatt) % | -47.85 | ||
| 3-Year Revenue Growth Rate | 9.3 | ||
| 3-Year EBITDA Growth Rate | 27.2 | ||
| 3-Year EPS without NRI Growth Rate | 21.9 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 4.83 | ||
| PS Ratio | 10.13 | ||
| EV-to-EBIT | -106.16 | ||
| EV-to-EBITDA | -167.67 | ||
| EV-to-Revenue | 10.15 | ||
| Current Ratio | 14.36 | ||
| Quick Ratio | 14.02 | ||
| Days Inventory | 40.03 | ||
| Days Sales Outstanding | 65.79 | ||
| Days Payable | 43.27 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.7 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 5.11 | ||
| Price-to-Median-PS-Value | 2.77 | ||
| Earnings Yield (Greenblatt) % | -0.94 |